Drug profile · INN
furosemide
APO-FRUSEMIDE
furosemide (APO-FRUSEMIDE) is a sodium-(potassium)-chloride cotransporter 2 inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — furosemide
- US status
- approved
- Class
- Cardiovascular system (C03)
- Route
- INJECTION
- Patents
- 0
- Programs
- 8
- Data quality
- 0.89
Quick answer
furosemide (APO-FRUSEMIDE) is a sodium-(potassium)-chloride cotransporter 2 inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium-(potassium)-chloride cotransporter 2 inhibitor
Primary target: Solute carrier family 12 member 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | unknown | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is furosemide?
furosemide (APO-FRUSEMIDE) is a sodium-(potassium)-chloride cotransporter 2 inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for furosemide?
APO-FRUSEMIDE is a marketed brand name for furosemide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of furosemide?
furosemide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.